Member of the Board since 2013 and Vice Chairman since June 2018.
Steen Riisgaard was born in 1951 and is a Danish national. He received an MSc in Microbiology from the University of Copenhagen. He began his career as a Research Fellow at Statens Serum Institute (SSI) and a Research Microbiologist at Foss Electric, Denmark.
Steen Riisgaard has over 34 years of experience in industrial biotechnology. He joined the Novozymes A/S (then Novo Nordisk A/S, Enzymes Division) research and development team in 1979. In 1982, he moved to Tokyo to start up a new enzymes research and development unit in the Novo Nordisk subsidiary, Novo Industry Japan Ltd. He returned to Denmark in 1985 and held a number of different positions in the company until 1989 when he was promoted to Corporate Executive Vice President of the Enzymes Business. In 2000, Steen Riisgaard became the President and CEO of Novozymes A/S, from the demerger from Novo Nordisk A/S, and served in that position until April 2013.
In addition to the role of Vice Chairman of the Novo Holdings A/S Board, Steen Riisgaard currently serves as Chairman of the Board for COWI Holding A/S and New Xellia Group A/S, both based in Denmark. Furthermore, he is Vice Chairman of the Board for the Villum Foundation, Board member for the Novo Nordisk Foundation, Board member and Substitute for the Chairman for Aarhus University in Denmark, all based in Denmark, and Board member in Corbion N.V. in the Netherlands.